That Fc-engineering can translate into clinically successful improvement of an antibody’s anti-tumor activity and may therefore also have potential to improve anti-myeloma activity of ICAM-1 antibodies was recently shown by the approval of tafasitamab-cxix, an Fc-engineered CD19 antibody for the treatment of diffuse large B cell lymphoma (52, 53). Here, CD19 is linked to plasma cell myeloma.